Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bisantrene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 9/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.97 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.97 |
| ▸ | NQO1 | P15559 | 1/20 | 0.97 |
| ▸ | DRD1 | P21728 | 1/20 | 0.97 |
| ▸ | ACHE | P22303 | 1/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.97 |
| ▸ | DRD3 | P35462 | 1/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.97 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.97 |
| ▸ | HTR6 | P50406 | 1/20 | 0.61 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.55 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.55 |
| ▸ | ASIC1 | P78348 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bisantrene SCHEMBL17819004 | 1.00 | ADRA2A (0.97) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL2852448 | 1.00 | ADRA2A (0.97) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL17819003 | 1.00 | ADRA2A (0.97) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL29665174 | 1.00 | ADRA2A (0.97) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL29398210 | 0.98 | ADRA2A (1.00) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL8906393 | 0.98 | ADRA2A (1.00) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL7207049 | 0.98 | ADRA2A (1.00) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL7472 | 0.98 | ADRA2A (1.00) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL1649622 | 0.97 | ADRA2A (0.97) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| SCHEMBL23323322 | 0.92 | ADRA2A (0.86) | ADRA2AADRA1ACHRM2HTR1AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10307 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4524131-A1 | SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | AlonBio Ltd. (IL) | 2025-03-19 | — | — | EP | claimed |
| US-12202803-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | ALONBIO LTD. (IL) | 2025-01-21 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| US-12109219-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | claimed |
| WO-2024162488-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CUCURBITACIN D FOR PREVENTING OR TREATING NEUROPATHIC PAIN | 주식회사 재인알앤피 | 2024-08-08 | — | — | WO | claimed |
| EP-4401780-A1 | AMORPHOUS PHOTOSENSITIZING PARTICLES, METHODS FOR THE PREPARATION THEREOF, AND METHODS FOR THE USE THEREOF | University of Maryland, College Park (US) | 2024-07-24 | — | — | EP | claimed |
| WO-2024088377-A1 | PYRIMIDOPYRROLE ANALOG | 香港科技大学 | 2024-05-02 | — | — | WO | claimed |
| WO-2024026505-A2 | DISRUPTION OF TELOCYTE ACTIVITY | PATEL AMIT (US) | 2024-02-01 | — | — | WO | claimed |
| US-20040092583-A1 | Treatment for inhibiting neoplastic lesions | SHANAHAN-PRENDERGAST ELIZABETH (IE) | 2004-05-13 | — | — | US | claimed |
| WO-2004028406-A1 | DRUG RELEASE FROM ANTITHROMBOGENIC MULTI-LAYER COATED STENT | MEDIPLEX CORPORATION (KR) | 2004-04-08 | — | — | WO | claimed |
| US-6702850-B1 | Multi-coated drug-eluting stent for antithrombosis and antirestenosis | MEDIPLEX CORPORATION KOREA (KR) | 2004-03-09 | — | — | US | claimed |
| EP-1351678-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | Shanahan-Prendergast, Elizabeth (IE) | 2003-10-15 | — | — | EP | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| US-20010049349-A1 | Antioxidant enhancement of therapy for hyperproliferative conditions | CRABTREE ACQUISITION CO, LLC | 2001-12-06 | — | — | US | claimed |
| CN-1261803-A | Antioxidant enhancement of therapy for hyperproliferative conditions | ATHEROGENICS INC (US) | 2000-08-02 | — | — | CN | claimed |
| EP-1019034-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | Atherogenics, Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| WO-1999001118-A9 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS INC (US) | 1999-05-20 | — | — | WO | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |